While global headlines screamed about the Trump administration's 100% pharmaceutical tariffs, Korean biopharmaceutical companies quietly emerged as structural winners.
What the fine print says: The U.S. Section 232 tariff order signed April 2 applies 100% duties on patented drugs from non-aligned countries (China, India). Korea landed in the 15% exception group alongside the EU and Japan -- thanks to KORUS FTA. But the bigger story: biosimilars and generics are completely exempt (0%, with a 1-year review clause).
Since biosimilars drive Korean biopharma exports -- Q1 2026 hit a record $4.16 billion -- the immediate impact for Celltrion and Samsung Bioepis is near-zero.
Three numbers that define the opportunity:
- Celltrion's Truxima holds 35.8% U.S. prescription share (Feb 2026) -- the first Korean biosimilar at #1
- Samsung Biologics' CDMO revenue reached 4.5T KRW in 2025 with $21.2B cumulative backlog
- Korea's 2026 biopharma export forecast: $30.4 billion, per Korea Biologics Association
The competitive nuance: India's Biocon Biologics ($6.6B market cap, $1.9B TTM revenue) gets the same 0% biosimilar rate. K-bio's real advantage is FDA GMP credibility, entrenched U.S. positions, and preemptive U.S. manufacturing -- Celltrion's Branchburg plant and Samsung Bio's Rockville, MD facility.
The watch item: The 1-year biosimilar exemption review. Both companies are building U.S. capacity as a hedge.
For the full analysis in Korean, visit Snakestock.
Top comments (0)